Article by Dr. Shaw on current status of ALK Inhibitor drugs

Dr. Shaw has written a comprehensive article on all 10 ALK Inhibitors being developed as of July 7, 2014.

It provides comparisons of testing status, concentration levels, side effects and much more. It also includes a 2 page list of references.

As I have posted elsewhere, it currently looks like only 8 ALK inhibitors are continuing clinical trials. Astellas recently appears to have stopped work on ASP-3026 and Teva recently appears to have stopped work on CEP-37440.

http://www.hematologyandoncology.net/files/2014/07/Awad1.pdf

For the full article you can goto http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215402/pdf/nihms636454.pdf

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery. Bookmark the permalink.

Leave a Reply